1. Home
  2. ANNX

as 05-24-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Founded: 2011 Country:
United States
United States
Employees: N/A City: BRISBANE
Market Cap: 458.4M IPO Year: 2020
Target Price: $14.33 AVG Volume (30 days): 1.9M
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.46 EPS Growth: N/A
52 Week Low/High: $1.57 - $8.40 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

ANNX Daily Stock ML Predictions

Stock Insider Trading Activity of Annexon Inc. (ANNX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Carson William H. ANNX Director May 1 '24 Buy $4.68 3,200 $14,982.40 6,400 SEC Form 4
Carson William H. ANNX Director Apr 8 '24 Buy $6.07 3,200 $19,411.20 3,200 SEC Form 4
Overdorf Michael ANNX EVP & CHIEF BUSINESS OFFICER Feb 16 '24 Sell $5.48 1,951 $10,691.48 85,641 SEC Form 4
Yednock Ted ANNX EVP & CHIEF INNOVATION OFFICER Feb 16 '24 Sell $5.51 2,604 $14,348.04 72,471 SEC Form 4
Lew Jennifer ANNX EVP & CHIEF FINANCIAL OFFICER Feb 16 '24 Sell $5.53 2,593 $14,339.29 82,058 SEC Form 4
Love Douglas ANNX PRESIDENT AND CEO Feb 12 '24 Sell $5.54 5,782 $32,032.28 196,121 SEC Form 4
Lew Jennifer ANNX EVP & CHIEF FINANCIAL OFFICER Feb 12 '24 Sell $5.54 1,809 $10,021.86 45,651 SEC Form 4
Overdorf Michael ANNX EVP & CHIEF BUSINESS OFFICER Feb 12 '24 Sell $5.53 1,349 $7,459.97 48,592 SEC Form 4
Yednock Ted ANNX EVP & CHIEF INNOVATION OFFICER Feb 12 '24 Sell $5.54 1,810 $10,027.40 36,075 SEC Form 4
Yednock Ted ANNX EVP & Chief Innovation Officer Dec 27 '23 Sell $4.52 21,000 $94,966.20 0 SEC Form 4
Satter Muneer A ANNX Director10% Owner Dec 26 '23 Buy $2.88 350,000 $1,008,000.00 7,406,024 SEC Form 4
Overdorf Michael ANNX EVP & Chief Business Officer Jul 11 '23 Sell $3.84 978 $3,751.71 45,802 SEC Form 4
Lew Jennifer ANNX EVP & Chief Financial Officer Jul 11 '23 Sell $3.84 1,057 $4,054.76 47,460 SEC Form 4

Share on Social Networks: